Evidence map›Paper›PMID 38836180›Full record

ArticleIntractable & rare diseases research2024

Reprogramming the future: Capitalizing on

Lisha Li, Taiwei Zhang, Zhaozhao Hua, Jing Wang, Hongmei Sun, Qian Chen, Yiyuan Zhou, Ling Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Intractable & rare diseases research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lisha LiLaboratory for Reproductive Immunology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Taiwei ZhangResearch Center of Obstetrical Eugenics, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guizhou, China.
Zhaozhao HuaDepartment of Obstetrics, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guizhou, China.
Jing WangLaboratory for Reproductive Immunology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Hongmei SunLaboratory for Reproductive Immunology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Qian ChenResearch Center of Obstetrical Eugenics, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guizhou, China.
Yiyuan ZhouResearch Center of Obstetrical Eugenics, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guizhou, China.
Ling WangLaboratory for Reproductive Immunology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Capitalizing on breakthroughs in reproductive genetics, the utilization of

Indexed as

embryo engineeringethical balancegenetic disordersreproductive geneticsstem cell therapies

Identifiers

PMID38836180
PMCPMC11145405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.